CLYMHealthcare · BiotechnologyThe 15 Wall Street analysts covering Climb Bio, Inc. hold a median 12-month price target of $28 — +200.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Climb Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (89): The shares have been drifting up relative to others.
Growth (33): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CLYM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +200.4% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | BTIG | Reiterates | Buy | $32 |
| 20 Oct 2026 | Deutsche Bank | Initiates | Buy | $28 |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $30 |
| 8 Sept 2026 | Oppenheimer | Maintains | Outperform | — |
| 8 Sept 2026 | Oppenheimer | Maintains | Outperform | $18 → $25 |
| 4 Sept 2026 | B. Riley Securities | Reiterates | Buy | $26 → $30 |
| 4 Sept 2026 | B. Riley Securities | Reiterates | Buy | — |
| 3 Sept 2026 | Baird | Maintains | Outperform | — |
| 3 Sept 2026 | Baird | Maintains | Outperform | $21 → $25 |
| 3 Sept 2026 | BTIG | Maintains | Buy | — |
| 3 Sept 2026 | BTIG | Maintains | Buy | $20 → $32 |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $24 |
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | $20 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $17 → $25 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 27 July 2026 | Wedbush | Maintains | Outperform | $17 → $20 |
| 27 July 2026 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLYM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Climb Bio, Inc. returned +395.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 38% of US stocks
Cheaper than 82% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 28% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Climb Bio, Inc. has a market value of $559.4M and an enterprise value of $377.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$57.6M.
Diluted earnings per share, trailing twelve months: $−0.83.
Free cash flow in the twelve months to 30 June 2026: −$53.1M.
Trailing P/E: −11.1×; forward P/E: −9.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Climb Bio, Inc. employs 28 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Climb Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Climb Bio announced it will present new clinical data for budoprutug in immune thrombocytopenia at the 68th ASH Annual Meeting and Exposition, scheduled for December 12–15, 2026, in New Orleans.
Why it matters — The presentation will provide CLYM watchers with an update on clinical data for budoprutug in ITP.
Climb Bio announced that members of its executive team will participate in the upcoming Guggenheim 3rd Annual Healthcare Innovation Conference.
Why it matters — The announcement informs CLYM watchers of an upcoming investor conference appearance by the company's executive team.
Climb Bio presented initial Phase 2 PrisMN data for budoprutug in pMN at an oral session during ASN Kidney Week 2026. The 200 mg dose demonstrated B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks; additional study data are anticipated in 2027.
Why it matters — The update gives CLYM watchers an early view of Phase 2 findings and the expected timing of further data.
Climb Bio and Mabworks reported CLYM116/MIL116 data showing more than 90% free APRIL suppression sustained through 12 weeks and an approximately 70% reduction in Gd-IgA1 at 12 weeks. The companies noted that NAVIGATE-2 is enrolling, with initial data expected in the first half of 2027, and that a global Phase 3 trial is expected to begin in 2027.
Why it matters — The reported biomarker results and stated trial timelines provide CLYM watchers updates on the program’s clinical progress.
Zacks Investment Research compares Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) with their sector performance so far this year.
Why it matters — The item places CLYM’s year-to-date performance in a sector comparison alongside HALO.
The 15 Wall Street analysts covering Climb Bio, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Climb Bio, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Climb Bio, Inc. 61 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Climb Bio, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +200.4% from the last close, and Ticker Nerd's factor model ranks Climb Bio, Inc. 61 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Climb Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLYM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $40 over the next 12 months.
Climb Bio, Inc. returned +395.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition". Climb Bio announced it will present new clinical data for budoprutug in immune thrombocytopenia at the 68th ASH Annual Meeting and Exposition, scheduled for December 12–15, 2026, in New Orleans.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases. Its current pipeline centers on budoprutug, an anti-CD19 antibody being studied for B-cell mediated and autoantibody-driven conditions, and CLYM116, an anti-APRIL antibody in development for IgA nephropathy. The company’s work is directed at diseases where abnormal immune activity can damage organs and create significant unmet medical need, including kidney and hematologic disorders. Climb Bio operates in the biopharmaceutical sector through preclinical research, clinical development, and translational programs designed to advance differentiated biologic medicines. Based in Wellesley Hills, Massachusetts, Climb Bio is positioned as a specialized developer of targeted immunology assets for complex immune disorders.
CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc · 28 employees · United States · https://climbbio.com
